新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 阿斯利康 » 阿斯利康完成$7亿收购阿特维斯品牌呼吸业务

阿斯利康完成$7亿收购阿特维斯品牌呼吸业务

来源:生物谷 2015-03-03 16:32

2015年3月3日讯 /生物谷BIOON/ --阿斯利康(AZN)今日宣布,已完成对阿特维斯位于美国及加拿大品牌呼吸系统业务的收购。该笔交易耗资7亿美元,包括一笔6亿美元的付款及1亿美元的额外付款。通过此次收购,阿斯利康获得了阿特维斯2种慢性阻塞性肺病(COPD)药物(Tudorza Pressair及Daliresp在美国和加拿大的商业化权利及另一种实验性COPD药物的研发和商业化权利。值得一提的是,Daliresp是慢性阻塞性肺病(COPD)市场首个也是唯一一个选择性磷酸二酯酶-4抑制剂。

正如此前所披露的,该笔战略性交易建立于阿斯利康2014年21亿美金收购Almirall呼吸系统业务的基础之上。这2笔交易,将大大增强阿斯利康在全球范围内的呼吸系统特许经营权。收购Almirall获得的呼吸系统资产包括:Eklira(aclidinium,阿地尼亚)、LAS40464(阿地尼亚+福莫特罗复方药,已获欧盟批准品牌名Duaklir Genuair,在美国处于在研)、LAS100977(abediterol,一种每日一次的长效β2受体激动剂LABA,处于II期临床)、处于临床前开发(LAS191351,LAS194871)和I期临床(LAS190792)的M3拮抗剂β2受体激动剂(MABA)平台、多个临床前项目。

此次交易收购的资产包括:Tudorza Pressair(阿地溴铵吸入性粉剂),一种抗胆碱能药物,适用于慢性阻塞性肺病(COPD)相关支气管痉挛(肺气道变窄)的长期维持治疗,包括慢性支气管炎和肺气肿;Daliresp(roflumilast,罗氟司特),是FDA批准的首个也是唯一一种选择性磷酸二酯酶-4(PDE-4)抑制剂,适用于严重慢性阻塞性肺病(COPD)患者降低急性发作风险,不适用于急性支气管痉挛的缓解。

呼吸系统专营权是阿斯利康的主要增长平台之一,也是其重点发展的领域之一;通过外部收购并结合自身的创新能力,阿斯利康意在加强哮喘和慢性阻塞性肺病(COPD)整个护理范畴的应对能力。(生物谷Bioon.com)

英文原文:AstraZeneca completes acquisition of rights to Actavis’ branded respiratory portfolio in the US and Canada

Tuesday, 3 March 2015

AstraZeneca today announced that it has completed the transaction to acquire the rights to Actavis’ branded respiratory business in the US and Canada.

As previously announced, the strategic transaction strengthens AstraZeneca’s respiratory franchise globally and builds on the acquisition of Almirall’s respiratory portfolio in 2014 by extending the company’s development and commercialisation rights into the US for both Tudorza Pressair and Duaklir Genuair.

AstraZeneca owns the development and commercial rights in the US and Canada to TudorzaTM PressairTM (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), and to Daliresp® (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD, in the US. AstraZeneca also owns the development rights in the US and Canada for LAS40464, the combination of a fixed dose of aclidinium with formoterol long acting beta agonist (LAMA/LABA) in a dry powder inhaler, which is approved in the EU under the brand name Duaklir® Genuair®.

On completion of the acquisition, AstraZeneca is paying Actavis $600 million of initial consideration and agreed to pay low single-digit royalties above a certain revenue threshold. AstraZeneca has also paid Actavis an additional $100 million for a number of contractual consents and approvals, including certain amendments to the ongoing collaboration agreements between AstraZeneca and Actavis.

NOTES TO EDITORS

About Tudorza Pressair

Tudorza Pressair (aclidinium bromide inhalation powder) 400 mcg is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. When given by inhalation, aclidinium produces bronchodilation by inhibiting the muscarinic M3 receptor in the airway smooth muscle. Aclidinium is rapidly hydrolyzed in human plasma into two major inactive metabolites.

Tudorza is administered using a multiple-dose dry powder inhaler, Pressair, which delivers 60 doses of aclidinium bromide powder for inhalation. The Pressair inhaler has a colored control window and audible “click” which confirm successful inhalation of the dose and a dose indicator to let patients know how many doses remain in the inhaler.

About Daliresp

Daliresp (500mcg) is a selective PDE4 inhibitor that is indicated as a treatment to reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Daliresp is a once-daily oral tablet and is the first and only selective PDE4 inhibitor approved by the FDA.

While the specific mechanism by which Daliresp exerts its therapeutic action in COPD patients is not well defined, it is thought to be related to the effects of increased intracellular cyclic AMP in the lung cells. Daliresp is not a steroid, is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

About COPD

COPD (chronic obstructive pulmonary disease) is a progressive disease associated mainly with tobacco smoking, air pollution or occupational exposure, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. It affects an estimated 300 million people worldwide and is predicted to be the third leading cause of death by 2020. Although COPD is widely regarded as a disease of the elderly, 50 per cent of patients are estimated to be between 50 and 65 years of age, meaning half of the COPD population is likely to be affected at a stage in their life when they are at the peak of their earning potential and are likely to have major family responsibilities.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库